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S270 Poster Session Ibeen in sustained remission for 41.4 to 56.3 months (3.45 to 4.7
years). Four patients died from relapsed disease at a median of 14.9
months (range 7.73-42) post-HCT, and one with failure to achieve
platelet engraftment, died from pulmonary hemorrhage at 4.5
months post-HCT.Table 1. RIC HCT for relapsed AML - Characteristics and
Results
Number (Range)
Total number of patients 10
Age (yrs), median 5.2 (1.8 – 10.6)
Lansky performance score $ 90 10
Disease status prior to HCT
CR1 1
CR2 3
CR3 3
Active disease 3
Neutrophil engraftment (ANC>500)
in days, median
16.5 (10-40)
Platelet engraftment (Plts >50,000)
in days, median
39 (16-42)
Acute GVHD, grades II-IV 4
Chronic GVHD (extensive) 1
Relapse 4
Time to relapse in days, median 114 (50-144)
Alive at last follow-up 5Overall survival was 61% (95% CI 37-100%) at 1 year and 51%
(95% CI 28-94%) at 3 years post-HCT. Disease free survival
was 42% (95% CI 20-87%) at 1 year and 31% (95% CI 13-
79%) at 3 years post-HCT. This modest success in our small co-
hort, indicate that RIC HCT can achieve long term and durable
remissions in patients with relapsed AML after first HCT, and of-
fer a potentially life-saving treatment option to this group of high
risk patients.SOLID TUMORS
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Background: Recent findings indicate that the tumor stroma is
a critical barrier for effective T-cell immunotherapies and that
eradicating the tumor stroma in addition to cancer cells has the po-
tential to increase antitumor effects. Cancer associated fibroblasts
(CAFs) are the central component of the tumor stroma and express
fibroblast activation protein (FAP), which is an attractive immuno-
therapeutic target since it is not expressed in normal tissues. The
objective of this project is to develop an adoptive immunotherapy
approach with antigen-specific T cells targeting FAP expressed on
reactive tumor stroma in addition to tumor antigens expressed on
cancer cells.
Methods:We constructed a FAP-specific chimeric antigen receptor
(CAR) using a FAP-specific single chain variable fragment that rec-
ognizes murine as well as human FAP. Mitogen activated T cells
were transduced with a retroviral vector encoding a second genera-
tion FAP-specific CAR with a CD28.zeta-signaling endodomain
(FAP-T cells).We then performed functional studies to characterize
the generated FAP-T cells.Results: FAP-T cells recognized and killed K562 cells genetically
modified to express FAP in contrast to non-transduced T cells
confirming specificity. FAP-T cells also recognized and killed a panel
of FAP-positive solid tumor cell lines (head and neck cancer, osteo-
sarcoma, breast cancer, andmelanoma). To evaluate if targeting only
the tumor stroma in vivo leads to a reduction of tumor growth we
took advantage of LCLs, which are FAP negative. Luciferase-ex-
preesing LCL were mixed with FAP-T cells, which recognize mu-
rine and human (mhFAP) or human FAP (hFAP), or non-
transduced T cells prior to s.c. injection into flanks of SCID mice.
While LCLs tumor readily established in mice injected with LCL/
hFAP-T cells or LCL/NT-T cells; LCL tumors either did not es-
tablish or their growth was markedly retarted (10- to 100-fold) in
mice injected with LCL/mhFAP-T cells as judged by serial biolumi-
nescence imaging.
Conclusion:We have constructed a FAP-specific CAR that enables
the rapid generation of FAP-T cells for targeting CAFs, the central
component of the tumor stroma. Targeting CAFs with FAP-T cells
resulted in marked reduction in tumor establishment and growth in
vivo. Experiments are in progress to evaluate if cotargeting tumor
cells and their supporting stroma results in enhanced tumor eradica-
tion.320
DOSE-DEPENDENT AND EPITOPE-SPECIFIC IN VIVO IRRADICATION OF
THE HUMAN OVARIAN CARCINOMA CELLS EXPRESSING THE WILLMS
TUMOR PROTEIN, WT1, IN NOD/SCID MICE, BY WT1 SPECIFIC T CELLS
MONITORED BY BIOLUMINESCENT IMAGING
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WT1 is expressed in 60-80% of acute leukemias and ovarian ade-
nocarcinomas. Its expression has been hypothesized to be critical for
the growth or survival of tumorigenic stem cells. Previously, allor-
eactive HLAA0201- T cells recongizing a complex of WT1-peptide
andHLA-A0201were reported to prevent growth of leukemicHLA-
A0201+CD34+Ph+CML progenitor cells in NOD/SCID mice. In
this study, we have assessed the capacity of WT1 CTLs lacking
the alloreactivity, restricted by different HLA alleles and WT1 de-
rived epitopes to prevent the outgrowth of two human ovarian ade-
nocarcinoma cells (OvCar) with low (13%) and high (43%)
expression of WT1 by FACS in NOD/SCID mice. For this study
epitope-specific and HLA restricted WT1-CTLs were generated
from PBMC of four normal donors by in vitro sensitization with au-
tologous EBV transfomed B cells (BLCL) loaded with the pool of
141 15-mers overlapping by 11aa and spanning the entire sequence
of WT1 protein. Each of the T cell lines was pre-incubated in vitro
for 8 hours at different E:T ratios (0:1, 5:1, 10:1, 50:1, 100:1) with
0.05x10^6 OvCar tumor cells transduced to express a luciferase re-
porter gene. The cell mixtures were injected i.p. into NOD/SCID
mice. Tumor growth was monitored weekly by the intensity of the
bioluminescent signal. In all animals injected with the tumor cells
alone the bioluminescent signal could be detected in the abdomen
by day 10-15 and increased steadily through 60 days of observation
(when all these mice died) while tumor engraftment was either mark-
edly inhibited (in OvCarWT1low) or completely abrogated (in Ov-
CarWT1high) by pre-incubation at 100:1 E:T ratio and correlated
with higher survival of the animals (80%) over a period of 120
days. The animals injected with the tumor cells preincubated with
the WT1-CTLs at 50:1 and 10:1 E:T ratio demonstrated weaker
bioluminescent signal in the abdomen which increased over the
course of the study while the pre-incubation of the tumor cells
with WT1-CTL at 5:1 ratio did not significantly affect tumor en-
graftment and growth. The inhibition of tumor growth was more ef-
ficient with the WT-CTL specific for the 398-506LKTHTTRTHT
epitope presented on the A0201 allele as compared to the A0301
or B0702 epitope ((-125)-(-117) RQRPHPGAL). These results suggest
that tumorigenic OvCar cells containing high propotion of WT1+
cells are succeptible to eradication in vivo by high doses of WT1-
CTL specific only for some but not every WT1 epitope selected
by T cells.
